Latest Breaking News On - Announces new positive long term data - Page 1 : comparemela.com

Results from the 24-week extension period of the phase 2b ENLIVEN trial showed sustained improvements in liver fat, fibrosis, and inflammation among those treated with 30 mg weekly and 44 mg biweekly pegozafermin.

Hank mansbachDrug administrationBreakthrough therapyAnnounces new positive long term dataNonalcoholic steatohepatitisGranted breakthrough therapy designationNonalcoholic fatty liver diseasePhase 2bLiver fatGlp 1 therapy